Sarcomatrix advances S-969 toward toxicology as it adds directors and external partners
AI Summary- Sarcomatrix updated development, governance and financing plans for S-969 and LAM-111.
- 43.5% refundable Australian research incentive is under evaluation for Phase 1 development.
- Brian Cain and Bill Ashton joined the board as independent directors.